Lindsey Cecil, MD
Family Medicine · Greenville, SCNPI 1235227935
Payments from drug & device makers
Across 305 payments — averaging $12.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$818
- Novo Nordisk$805
- AstraZeneca$397
- Boehringer Ingelheim$249
- Takeda Pharmaceuticals U.S.A., Inc.$240
- Lilly USA, LLC$238
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,937100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $818 |
| Novo Nordisk | 77 | $805 |
| AstraZeneca | 22 | $397 |
| Boehringer Ingelheim | 16 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $240 |
| Lilly USA, LLC | 15 | $238 |
| Amgen | 16 | $206 |
| Pfizer | 10 | $167 |
| Esperion Therapeutics, Inc. | 5 | $72 |
| Amarin Pharma, Inc. | 4 | $68 |
| Eisai Inc. | 4 | $60 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Boston Scientific | 2 | $47 |
| GSK | 3 | $47 |
| Astellas Pharma US Inc | 2 | $44 |
| Mckesson Medical-surgical, Inc. | 1 | $37 |
| Novartis | 2 | $33 |
| Inari Medical, Inc. | 1 | $30 |
| Bayer | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Corium, LLC | 2 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$3,949 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 58 | $65,489 |
| JardianceEmpagliflozin | 54 | $46,611 |
| JanuviaSitagliptin Phosphate | 38 | $31,179 |
| OzempicSemaglutide | 21 | $27,493 |
| RybelsusSemaglutide | 14 | $16,259 |
| FarxigaDapagliflozin Propanediol | 11 | $15,619 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $14,047 |
| TrulicityDulaglutide | 13 | $12,586 |
| TrintellixVortioxetine Hydrobromide | 11 | $10,347 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,422 |
| EliquisApixaban | 13 | $6,999 |
| VascepaIcosapent Ethyl | 12 | $4,063 |
| Duloxetine Hcl | 72 | $3,822 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,664 |
| SynthroidLevothyroxine Sodium | 35 | $2,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $249 | $46,61154 claims |
| Novo NordiskOzempic, Rybelsus | $805 | $43,75235 claims |
| MerckJanuvia | $17 | $31,17938 claims |
| AstraZenecaFarxiga | $397 | $15,61911 claims |
| GSKBreo Ellipta | $47 | $14,04719 claims |
| Lilly USA, LLCTrulicity | $238 | $12,58613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $240 | $10,34711 claims |
| PfizerEliquis | $167 | $6,99913 claims |
| AbbVieSynthroid | $818 | $2,64135 claims |
| Sanofi-aventis U.S. LLCLantus | $12 | $82014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Greenville
- James FranklinGreenville$3.5M
- Jeffrey HarrisGreenville$3.4M
- Christopher DavisGreenville$2.7M
- Harlicia FarleyGreenville$1.1M
- James WallaceGreenville$708K
- Eric Garcia-TorresGreenville$102K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.